About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR

About Us
  Research & Development
  Branded Formulations
  Financial Results
  - Investor Call Invite
  - Investor Presentation
  - Disclosure to Stock Exchange
  - Annual Reports

 Annual Report 2019

Annual Report 2018

  - Biocon's Journey of Fortitude
  - Biocon Profile
  - CMD Profile
  - Video Gallery




  Facilities Virtual Tour

Biocon is Asia’s premier fun88官网 company that is driven by the vision to make a difference to global healthcare through improved access to high quality, life-saving biotherapeutics by making them affordable for patients across the world.

We have evolved from manufacturing pharmaceuticals like statins and immunosuppresants, to discovering, developing and producing biologics in chronic therapies such as diabetes, oncology and immunology for global markets. This has translated into a diversified and differentiated pipeline of fermentation-derived complex generics, biosimilars that include insulins and monoclonal antibodies, and novel biologics.

Biocon was among the early movers in industry to pursue a high risk strategy of developing biosimilars for global markets. Through our ‘Made in India’ biosimilars business, we seek to pursue a humanitarian path that will provide affordable access to high quality generic biologics to make a difference to diabetes, cancer and autoimmune diseases. We have succeeded in bringing the benefit of high quality biosimilars to patients in India, other emerging market countries in Latin America, Africa, Middle East & Turkey, Asia-Pacfic regions and also now in developed markets of U.S., EU and Japan.

A combination of specialized talent, state-of-the-art research and manufacturing infrastructure and a culture of deep science and regulatory compliance have differentiated us in the marketplace and given us a distinct competitive edge. It has also led to Biocon being recognized as a credible global fun88官网s player.

fun88,乐天堂fun88,fun88乐天堂备用网站


Biocon Performance Highlights of Q1FY20 by Kiran Mazumdar-Shaw, CMD, Biocon Ltd.

Biocon Corporate Overview


Company Announcements


Sep 26, 2019 
Kiran Mazumdar-Shaw Promises to Enable Universal Access to rh-Insulin by Reducing Prices to Less than 10 US cents /Day for LMICs

Sep 24, 2019 
Biocon Biologics Expands its R&D Footprint Through Acquisition

Sep 20, 2019 
Company Statement: U.S. FDA Completes Pre-Approval Inspection of Two New Biocon Biologics Facilities in Bengaluru

  Media Coverage  

Sep 25, 2019:
Blueprint for a Healthy India

Sep 25, 2019:
Biocon subsidiary acquires Pfizer’s R&D facility in Chennai

Aug 22, 2019:
Ramp-up of biosimilar portfolio to boost Biocon

Jul 30, 2019:
Our aim is to be a global leader in biosimilars biz: Biocon Biologics CEO



Biocon Malaysia







Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved